Navigation Links
Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Date:3/25/2008

PALO ALTO, Calif., March 25 /PRNewswire/ -- Anacor Pharmaceuticals today announced results from a Phase 2a clinical trial of AN2728, an investigational topical anti-inflammatory drug, in patients with psoriasis. The study met its primary endpoint and all secondary endpoints.

In 69 percent of patients, the area treated with AN2728 scored better at the end of therapy than the area treated with the vehicle ointment, compared with six percent of patients in whom the vehicle-treated areas were superior. These results were statistically significant (p<0.001). No drug-related safety issues were reported.

"The results of this study suggest that AN2728 can effectively treat psoriasis in a clinical setting. In addition, plaques treated with AN2728 continued to improve over the course of the 28 days of therapy, suggesting longer-term treatment may have an even greater effect," said Karl R. Beutner, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Anacor. "These results are encouraging for both AN2728 and our entire anti-inflammatory program."

AN2728 is a novel boron-containing small molecule that inhibits the release of pro-inflammatory cytokines including TNF-alpha, IL-12, and IL-23, known mediators of the inflammation associated with psoriasis.

The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of an ointment containing a 5% concentration of AN2728 with patient self-application. Patients with psoriasis commonly have similar areas of psoriasis on their left and right, or front and back sides. The study took advantage of this bilateral characteristic of psoriasis. In this trial, 35 patients treated one of their areas of psoriasis with AN2728 ointment, and a matching area on the opposite side with vehicle alone, twice a day for four weeks.

In addition to this Phase 2a study, two Phase 1b dose-ranging trials have investigated the effects of concentration and formulation
'/>"/>

SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
5. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013   RxAlly , a first-of-its-kind alliance ... the publication of a white paper entitled Personalized ... The white paper highlights an unprecedented solution for ... engagement to avert strains on the health care ... a range of individually-tailored, pharmacist-provided clinical and consultative ...
(Date:5/20/2013)... -- Volcano Corporation (NASDAQ: VOLC ) a leading ... to enhance the diagnosis and treatment of coronary and ... efforts to expand research and innovation surrounding its physiology ... ® (Instant Wave-Free Ratio™) 1 technologies, via ... 2013 in Paris . ...
(Date:5/20/2013)... Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Directors declared, at its meeting on May 16, 2013, ... for the third quarter of fiscal 2013.  The dividend ... of record on June 7, 2013. About ...
Breaking Medicine Technology:RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4Landauer, Inc. Declares Regular Cash Dividend 2
(Date:5/21/2013)... Beginning May 21st, 2013, DTP Sales ... 8000, the newest in digital recording technology, to the ... product for anyone looking to get the most from ... 8000 is expected to have revolutionary options and ... voice recorder features and highlights: , ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Tools4ever, the ... has made its Self Service Reset Password Management (SSRPM) ... employees can now use the service on mobile systems ... end users can easily reset their Windows passwords anywhere, ... of questions correctly, the user may then reset his ...
(Date:5/21/2013)... HealthDay Reporter , , MONDAY, May 20 ... millions of people with chronic obstructive pulmonary disease ... among older patients, a new large Canadian study ... age 65 who are prescribed long-acting bronchodilators -- ... as Serevent). Both medications are commonly used to ...
(Date:5/21/2013)... PHILADELPHIA The surgical management of non-small cell lung ... the race of the patient, according to a new ... I and Stage II NSCLC is surgery," said researcher ... in Omaha, Nebraska. "In our study of more than ... the years 2000 and 2010, we found statistically significant ...
(Date:5/21/2013)... 2013, PHILADELPHIA ─ A novel approach to obstructing ... of asthma has shown promise in a Phase ... , Their research will be presented at the ... simultaneously online in the New England Journal ... trial tested the efficacy and safety of the ...
Breaking Medicine News(10 mins):Health News:DTP Sales & Service Announces Upcoming Availability Of Philips Pocket Memo 8000 Series 2Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3
... to move court against the bans handed to dope-tainted fast ... Cricket Board (PCB) has pleased the outside world and the ... was not meted out to the two," PMA president Umer ... ,On Wednesday, a specially constituted PCB tribunal had banned Shoaib ...
... An issue which is likely to arouse strong feelings either ... medical college in Britain - the proposal suggests mercy killing ... Royal College of Obstetricians and Gynaecology put forth this recommendation ... of a lesser god" who are being kept alive because ...
... Harassment' at the workplace faced by women doctors and nurses ... not ready to come out openly against it.// , ... in-depth interviews of women employees in two government and two ... out this news in which several doctors and nurses, including ...
... Awareness Day falls on November 7 and the theme ... be participating in a marathon on that day// to ... the dreaded disease. ,"Run 4 Cancer" will ... Kamala Nehru Memorial Hospital. Commissioner Allahabad Division RN Tripathi ...
... Russia a country known for its lax regulations regarding ... in liquor without any person// in authority ever raising ... when recent estimates prove that over forty two thousand ... alcoholism. However a closer scrutiny has also revealed that ...
... called off further enrollment for the clinical trial it had ... of the patients who were participating in the clinical trial ... ,The CEO of the company James Bianco has reiterated that ... do not seem to have been triggered of by any ...
Cached Medicine News:Health News:Consider Euthanasia For Severely Disabled Babies, College Tells Doctors 2Health News:Doctors, Nurses Face Sexual Harassment At Work Place 2Health News:Awareness about Women's Cancers- A National Concern 2Health News:Multiple deaths forces cancer trial to be called off 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: